Research programme: anti-fungals - Agrivir

Drug Profile

Research programme: anti-fungals - Agrivir

Latest Information Update: 22 Sep 2006

Price : $50

At a glance

  • Originator Agrivir
  • Developer Agrivir; BioAgri; Medivir AB
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 31 Dec 2005 Discontinued - Preclinical for Mycoses in Sweden (unspecified route)
  • 23 Oct 2001 New profile
  • 23 Oct 2001 Preclinical development for Mycoses in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top